Humana to limit coverage of pricy Biogen drug

Insurance giant Humana has announced it will cover Biogen ’s recently-approved rare disease drug Spinraza, but only for patients with the most severe type of the disorder, called spinal muscular atrophy. Humana (NYSE: HUM) issued its coverage policy on Wednesday for Spinraza, a first-of-its-kind treatment that was approved Dec. 23 and is one of the most expensive rare disease drugs in history. Humana said it would only cover patients with Type 1 SMA, not Types 2 through 4, despite the drug’s…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news